Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Hand holds a cut-out puzzle piece shaped like a human brain, backlit by sunlight against a bright yellow background, symbolizing creativity and problem-solving.

Parkinson’s disease

AC Immune’s Parkinson’s Immunotherapy Appears to Slow Disease Progression

In a first for the Parkinson’s field, AC Immune’s immunotherapy has stabilized key biomarkers that suggest an effect on the disease’s course.

December 11, 2025

1 min read

Annalee Armstrong

Dartboard with three darts in the bullseyes. 3D illustration

Obesity

Lilly’s Retatrutide Scores Triple Trial Triumph With 26% Weight Loss, But New Safety Signal Emerges

Analysts were hoping for a safety profile similar to what was achieved in Phase II but an abnormal sense of touch, called dysesthesia, has emerged in the late-stage TRIUMPH-4 trial.

December 11, 2025

3 min read

Annalee Armstrong

Concept of freedom, with a man who opens a breach in a wall to escape from his prison and pass from the shadows to the light.

FDA

Opinion: FDA Is Built on Predictability and Expertise, Not Norm-Breaking

The FDA is becoming deeply compromised and increasingly at risk of being permanently transformed in ways contrary to its mission, history and culture.

December 11, 2025

5 min read

Steven Grossman

Pictured: Entrance to Pfizer's office in Belgium

Breast cancer

Pfizer Builds Case for Tukysa as ‘New Standard Regimen’ in First-Line Metastatic Breast Cancer

While new late-stage data point to some liver toxicity signals, analysts at BMO Capital Markets said Tukysa’s efficacy outcomes “appear to more than make up for any safety concerns.”

December 11, 2025

2 min read

Tristan Manalac

Creative collage illustration of financial business. Two businessmen shaking hands for partners agreement. Conceptual illustration of success deal, corporate ethic, connection.

Weight loss

Zealand Bets up to $2.5B in Metabolic Pact With Chinese Biotech

Also on Thursday, Zealand held its Capital Markets Day in London, outlining the strategy for its weight management franchise in the near-term, including launching five products by 2030.

December 11, 2025

2 min read

Tristan Manalac

Pictured: Roche Diagnostics building in California

Breast cancer

Roche’s Oral SERD Cuts Death Risk by 30% in Early-Stage Breast Cancer

While overall survival remains immature, results so far show a clear trend in favor of Roche’s giredestrant.

December 11, 2025

2 min read

Tristan Manalac

Pictured: Pfizer's signage outside its office in Canada/iStock, JHVEPhoto

Layoffs

Pfizer’s Cost Cuts Claim 200+ Jobs in Switzerland: Report

Pfizer is in the midst of an aggressive, multi-year cost-cutting effort, which so far has left nearly 2,000 people jobless.

December 11, 2025

2 min read

Tristan Manalac

IN PARTNERSHIP WITH ANAPTYSBIO

Beyond the Gluten-Free Diet: A New Era in Celiac Disease Treatment

In this episode of Denatured presented by AnaptysBio, Jennifer Smith-Parker speaks to Dr. Joe Murray, Mayo Clinic; Marilyn Geller, the Celiac Disease Foundation; and Dr. Paul Lizzul, AnaptysBio, about the challenges and opportunities facing celiac disease treatment.

December 11, 2025

1 min read

Jennifer Smith-Parker